In this study, Tung et al. demonstrated that wtp53 suppressed Nrf2 promoter activity in NSCLC cells; however, in p53 mutant cells promoter activity was not suppressed, resulting in increased mRNA levels of Nrf2 and the anti-apoptotic proteins, Bcl-2 and Bcl-xL, ultimately contributing to cisplatin resistance [180]. The gene discussed is TP53; the disease is non-small cell lung carcinoma.